Heron Therapeutics Inc vs D Wave Quantum Inc — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while D Wave Quantum Inc trades at $14.55 (market cap $5.54B). The key difference: D Wave Quantum Inc is far larger — about 81.5× Heron Therapeutics Inc's market cap, and D Wave Quantum Inc is more actively traded (16,671,452 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and D Wave Quantum Inc for 32 Days on average.
| HRTX | QBTS | |
|---|---|---|
Market Cap | $68.01M | $5.54B |
Volume | 1,891,941 | 16,671,452 |
Sector | Health | Technology |
52-Week High | $1.49 | $44.78 |
52-Week Low | $0.27 | $12.98 |
Typical Hold Time | 35 Days | 32 Days |
Enterprise Value | $174.75M | $5.04B |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
D-Wave Quantum (QBTS) trades at $14.52, down 4.6% on the day, amid a bearish technical signal and negative earnings trends. The company reported a net loss of $355 million in 2025 on $25 million in revenue, with a deeply negative net income margin. However, all 13 analysts covering the stock maintain a Buy rating with a consensus price target of $34.38, suggesting significant upside potential from current levels.
The outlook is highly speculative, balancing substantial analyst optimism against severe financial losses and ongoing securities investigations. Investment opportunity hinges on the company's ability to commercialize quantum technology, but risks include cash burn, competitive pressures, and legal uncertainties that could impede shareholder value creation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →